LBI is an internationally renowned organization dedicated to research in the fields of tissue engineering, stem cells, and regenerative medicine.
"Collaborating with the Ludwig Boltzmann Institute gives Hemostemix an opportunity to explore in depth the mechanism of action of its lead product ACP-01 for a refined understanding of how ACP-01 fundamentally works to improve blood flow," said Dr. Ina Sarel, vice president of research and development at Hemostemix.
"We value LBI’s expertise with novel preclinical models that enable us to optimize future applications for ACP-01."
"This research collaboration agreement comes at the right time in the growth of Hemostemix," said Dr. Elmar Burchardt, president and CEO of Hemostemix.
"With our multicenter, double-blind, and placebo-controlled phase-2 trial of ACP-01 for critical limb ischemia in progress across international sites under the same clinical protocol, the scientific expertise of the Ludwig Boltzmann Institute will help us develop Hemostemix technology for novel therapeutic applications. Furthermore, demonstrating the mechanism of action of ACP-01 will make Hemostemix more attractive to commercial partners."